Are you an experienced clinician, or scientist, with clinical research experience in either immunology, cell therapy or metabolism-related diseases? Would you like to be part of a dedicated and high performing team of clinical research professionals, clinical scientists, and physicians who are translating rigorous scientific discoveries into early and late phase clinical development plans and studies across a wide range of chronic and debilitating diseases?
The AstraZeneca BioPharma Fellows Program, is a newly developed, competitive, 12-month immersive research and training program in clinical development for early-career physicians and scientists who are inspired by science and by how clinical development has the potential to transform patient care. As part of the selected cohort of fellows, you'll have an opportunity to learn from a diverse group of experts across the drug development continuum and play a pivotal role in channeling our scientific capabilities to make a positive impact on changing patients' lives. We are currently recruiting for the 2025 class, aimed at beginning the fellowship in the summer of 2025.
This is an office-based role that is located at AstraZeneca's vibrant R&D site in Boston (Seaport Blvd), Massachusetts, transferring to our purpose-built facility in Kendall Square once it opens in 2026.
At AstraZeneca, we are dedicated to building an outstanding work environment where diversity and inclusivity thrive, encouraging collaboration and trust among our team members. We're pushing the boundaries of science to deliver life-changing medicines to patients, with a passion for discovery and a pipeline to show for it. We are dedicated to improving the health care and quality of life for patients across a wide range of diseases and disorders by developing innovative therapies that address unmet clinical needs and provide clinicians with novel evidence-based treatment options to optimize the care of their patients.
Who we Are
In the Respiratory and Immunology (R&I) Late Clinical Development team, we are investigating the novel and advanced science of R&I diseases to deliver life-changing medicines to patients. Our ambition is to pioneer innovative research and explore novel therapeutic pipelines to become the worldwide leading company in immunology. With such passion, our portfolio includes various gastrointestinal, rheumatology, immunology, and respiratory diseases.
In Immunology Cell Therapy, we are advancing our growing ambition in immunology by driving next-generation cell therapies (including CAR-T cells and other modalities) with the potential to restore immune tolerance and possibly cure immune-mediated and inflammatory diseases. Our innovative approaches and deep expertise in cell therapy give us an opportunity to deliver life-changing therapeutics to patients. This is an excellent program to provide medical and scientific input to T-cell therapy clinical stage assets working in collaboration with and learning from cross-functional teams including basic research, clinical pharmacology and translational medicine, clinical operations, medical directors, safety, regulatory affairs, biostatistics, cell product manufacturing, and commercial.
In the Cardiovascular, Renal & Metabolism (CVRM) Early Clinical Development team, we are investigating the drivers of CVRM disease progression through ground-breaking scientific methods and data-driven drug discovery approaches. In this context, we are investigating a wide range of different drug modalities from our rich CVRM portfolio of compounds across diverse metabolic patient populations including obesity, T2DM, and MASH.
Early Clinical Development (ECD), part of the Early CVRM organization, is where science meets clinical drug development with a focus upon delivering innovative, early phase clinical studies and accelerating human target validation while collaborating closely with our late phase clinical development and regulatory colleagues who guide our pivotal phase 3 clinical studies. We are a diverse team of experienced physicians and clinical scientists who collaborate to delineate early phase clinical development strategies, design innovative phase I-IIb clinical trials, develop and validate novel surrogate endpoints, and translate scientific ideas to proof-of-concept studies in targeted patient populations.
What you'll do
The 2025 AstraZeneca BioPharma Fellows will join AstraZeneca at a time of tremendous growth and acceleration in the BioPharma portfolio. This rotational program will allow you to work in Early and Late Clinical development, ending with a fixed placement in one of our development teams.Working in a fast-paced and dynamic work environment, you will experienceincreasing levels of responsibility, following a structured learning plan in the following domains:
Subscribe to job alerts and upload your resume!
*By registering with our site, you agree to our
Terms and Privacy Policy.